Rocket Pharma Limited   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Grand Cayman Cayman Islands (2015)

Organization Overview

First Clinical Trial
2015
NCT01331018
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Rocket Pharmaceuticals Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

Key: Rocket Pharma Limited (0) Acquired (2)

timolol (blocadren) (2 trials)

trabodenoson (5 trials)

Drugs in Phase 2 Trials (5)

Key: Rocket Pharma Limited (3) Acquired (2)

ino-1001 (2 trials)

latanoprost (xalatan) (2 trials)

Mozafancogene autotemcel (3 trials)

rp-a501 (2 trials)

rp-l201 (2 trials)

Drugs in Phase 1 Trials (8)

genetically engineered hematopoietic stem cells (1 trial)

methylprednisolone (medrol) (1 trial)

plerixafor (mozobil) (1 trial)

prednisone (meticorten) (1 trial)

rp-a601 (1 trial)

rp-l301 (1 trial)

rp-l401 (1 trial)

sargramostim (leukine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 2)

Anemia, Hemolytic, Congenital Nonspherocytic (Phase 1)

Fanconi Anemia (Phase 2)

Fanconi Syndrome (Phase 2)

Glycogen Storage Disease Type IIb (Phase 1)

Osteopetrosis (Phase 1)

Pyruvate Metabolism, Inborn Errors (Phase 1)

Tissue Adhesions (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 18
  • # of Trial APIs: 15